SparingVision acquires GAMUT Therapeutics; expanding novel ocular disease pipeline
SparingVision will acquire GAMUT Therapeutics, the biotech behind a gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa (RP).
GAMUT is a spin-out of the Institut de la Vision in Paris, focused on the research of scientific founder Dr. Deniz Dalkara and her collaborators. It was started in 2020 with seed funding from Advent France Biotechnology.
SparingVision’s SPVN06 already addresses mid-stages of rod-cone dystrophies, while GAMUT’s SPVN20 addresses late stages: giving SparingVision the opportunity to address different stages and potentially combine both products.
SPVN20 joins SPVN06